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1. INTRODUCTION {#cam42282-sec-0001}
===============

Globally, colorectal cancer (CRC) is one of the most common human cancers and the fourth leading cause of cancer‐related death among males and females, with an estimated 1.4 million new cases and 694 000 deaths from the disease annually.[1](#cam42282-bib-0001){ref-type="ref"} In Taiwan, CRC ranked as the fourth leading cause of death, accounting for 14 965 cases diagnosed in 2012. CRC has increased significantly from 1990, with a growth rate of more than 2% per year worldwide. The likelihood of developing CRC is strongly correlated with old age, male gender, smoking, drinking alcohol, lack of exercise, being overweight, the consumption of red and/or processed meat, and a history of diabetes.[2](#cam42282-bib-0002){ref-type="ref"}, [3](#cam42282-bib-0003){ref-type="ref"}

Epidermal growth factor receptor (EGFR) has been recognized as an effective anticancer target during the last few years. Monoclonal antibodies used to block EGFR in combination with chemotherapy or radiation have yielded improved outcomes in CRC patients with extended *RAS* wild‐type tumors. Mutations in the *RAS* and *BRAF* genes are harmful to anti‐EGFR therapy in metastatic CRC (mCRC).[4](#cam42282-bib-0004){ref-type="ref"} *RAS* and *BRAF* oncogene mutations are mutually exclusive and occur in 36.97% and 4.24% of CRC patients, respectively, as described in our previous work.[5](#cam42282-bib-0005){ref-type="ref"} Thus, identifying the unique genomic profiles and molecular phenotypes could help effectively establish the best treatment method in patients with anti‐EGFR therapy resistance.

CRC is one of the most interesting fields of next‐generation sequencing (NGS) application. The number of studies employing the NGS technique continues to increase. The Cancer Genome Atlas (TCGA) project studied more than 224 CRC cases and showed that 24 genes, including *APC*, *TP53*, *SMAD4*, *PIK3CA*, and *KRAS*, contained significant mutations. Three genes (*ARID1A*, *SOX9*, and *FAM123B/WTX*) were frequently mutated.[6](#cam42282-bib-0006){ref-type="ref"} Ashktorab et al analyzed 63 Iranian patients using targeted exome sequencing and found higher mutation rates of *MSH3*, *MSH6*, *APC*, and *PIK3CA* and hypothesized a larger role for these genes in CRC. They suggested the adoption of a specific informed genetic diagnostic protocol and tailored therapy in this population.[7](#cam42282-bib-0007){ref-type="ref"} Because patients with *RAS* wild‐type CRC can be non‐responders to EGFR‐targeted therapy, Geibler et al analyzed cell lines and tumor specimens to identify prediction markers by NGS, *EGFR* methylation and expression, and E‐cadherin expression. The authors revealed *ATM* mutations and low E‐cadherin expression as novel supportive predictive markers.[8](#cam42282-bib-0008){ref-type="ref"} Adua et al analyzed primary tumor and liver metastasis samples from 7 *KRAS* wild‐type patients and compared the genotypes of 22 genes associated with anti‐EGFR before and after chemotherapy. The results showed marked genotypic differences between pre‐ and post‐treatment samples, which were likely attributable to tumor cell clones selected by therapy.[9](#cam42282-bib-0009){ref-type="ref"} Gong et al analyzed 315 cancer‐related genes and introns of 28 frequently rearranged genes in 138 mCRC cases using FoundationOne. They identified a novel KRAS mutation (R68S) associated with an aggressive phenotype. The authors reported that *ERBB2*‐amplified tumors may benefit from anti‐HER2 therapy, and hypermutated tumors or tumors with high tumor mutational burden with MSI‐H or *POLE* mutation may benefit from anti‐PD‐1 therapy.[10](#cam42282-bib-0010){ref-type="ref"}

This study examined genetic alterations in CRC in a Taiwanese population. We performed whole‐exome sequencing (WES) to detect the mutational status in all human protein‐coding genes using fresh frozen tissue from 32 Taiwanese patients with CRC.

2. MATERIALS AND METHODS {#cam42282-sec-0002}
========================

2.1. Study patients and tumor samples {#cam42282-sec-0003}
-------------------------------------

This study was approved by the China Medical University Hospital Institutional Review Board. A summary of all patient characteristics is provided in Table [1](#cam42282-tbl-0001){ref-type="table"}. Patients ranged in age from 35 to 90 years, with a median age of 62 years. DNA was extracted using a QIAamp^®^ DNA Micro Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer\'s instructions. Extracted DNA was immediately stored at −20°C until further processing. DNA concentration was measured by the Qubit dsDNA Assay Kit (Life Technologies, Carlsbad, CA, USA).

###### 

Clinical features of 32 colorectal cancer patients

  Characteristic                   n (Frequency)
  -------------------------------- ---------------
  Age (years)                      
  Average: 60.47                   Range: 35‐90
  Sex                              
  Male                             20
  Female                           12
  Differentiation                  
  Low                              2
  Middle                           28
  Middle to Low                    2
  AJCC stage                       
  I                                4
  IIA                              15
  IIIB                             5
  IIIC                             2
  IVA                              1
  IVB                              4
  NA                               1
  Regional lymph node metastasis   
  N0                               19
  N1                               4
  N2                               7
  NA                               2
  Site                             
  Rectum                           8
  Colon                            24
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2.2. WES and data analysis {#cam42282-sec-0004}
--------------------------

DNA libraries were prepared using the Illumina TruSeq Exome Library Prep Kit and sequenced on the Illumina NextSeq 500 platform. Base calling and quality scoring were performed by an updated implementation of Real‐Time Analysis in NextSeq500. Bcl2fastq Conversion Software was used to demultiplex data and convert BCL files into FASTQ files. Sequenced reads were trimmed for low‐quality sequences and aligned to the human reference genome (hg 19) using Burrows‐Wheeler Alignment.[11](#cam42282-bib-0011){ref-type="ref"} Finally, single nucleotide polymorphisms and small insertion and deletion mutations were called in individual samples by the Genome Analysis Toolkit and VarScan using default settings.[12](#cam42282-bib-0012){ref-type="ref"}, [13](#cam42282-bib-0013){ref-type="ref"} We then performed ANNOVAR to functionally annotate genetic variants.[14](#cam42282-bib-0014){ref-type="ref"} The following criteria were used to select confident somatic single nucleotide variants: mutant allele frequency \>5%, global minor allele frequency \<1%, or NA (comparing the ExAC and 1000 Genome Databases data), eliminating known harmless variants present in ClinVar or the in‐house polymorphism database, and predicted to be pathogenic by all three software programs (SIFT, PolyPhen‐2, and CADD).

2.3. Statistical analysis {#cam42282-sec-0005}
-------------------------

Comparisons between clinicopathological features and the status of critical pathway mutations in CRC were performed using Fisher\'s exact test. Two‐sided *P*‐values \< 0.05 were considered statistically significant.

3. RESULTS {#cam42282-sec-0006}
==========

3.1. WES analysis and coverage {#cam42282-sec-0007}
------------------------------

Using massive parallel sequencing on a NextSeq platform, we generated a mean of 157 M raw reads per sample, of which 141 M were aligned to the human reference genome (hg19; Table [2](#cam42282-tbl-0002){ref-type="table"}). The mean depth of the target regions for the 32 samples was 119× (range 34.79‐197.53×). The coverage of the target regions exceeded 97.97%. Figure [1](#cam42282-fig-0001){ref-type="fig"} is an overview of our approach used to identifying variants.

###### 

Alignment and coverage statistics for 32 colorectal cancer patients

  Patient ID   Total raw reads   Total effective reads   Reads mapped to genome   Average sequencing depth on target   Coverage on target (%)
  ------------ ----------------- ----------------------- ------------------------ ------------------------------------ ------------------------
  16           82 864 708        66 661 376              66 657 979               47.14                                98.44
  25           69 110 948        56 550 852              56 544 621               40.16                                98.00
  36           68 965 280        56 546 730              56 539 081               38.51                                98.10
  50           356 294 022       326 553 966             326480947                188.98                               99.01
  56           75 141 654        60 803 428              60 794 779               43.41                                97.97
  62           71 243 396        58 278 776              58 270 698               40.07                                98.12
  71           70 086 092        57 388 574              57 381 580               41.24                                98.05
  89           63 437 554        50 916 024              50 913 067               37.87                                98.35
  93           59 001 856        47 743 596              47 736 346               34.79                                98.03
  98           269 310 102       24 7274 550             247 189 402              197.53                               99.37
  99           63 078 404        51 065 200              51 058 021               37.07                                98.10
  103          66 173 134        52 911 932              52 907 746               39.03                                98.31
  CC01         202 308 880       182 302 644             182 249 487              148.28                               98.93
  CC02         196 162 260       179 076 152             179036670                137.71                               98.86
  CC03         149 966 094       138 301 996             138 263 040              124.07                               99.16
  CC04         188 762 344       175 316 188             175 287 324              154.65                               99.17
  CC05         174 170 480       161 466 102             161 439 317              143.79                               98.92
  CC06         163 747 730       151 903 466             151 881 413              128.67                               99.13
  CC07         180 821 438       167 186 452             167 155 256              133.86                               99.00
  CC08         174 412 902       161 772 158             161 747 641              146.76                               99.17
  CC10         178 559 504       160 173 326             160 136 434              148.31                               99.15
  CC11         202 264 106       182 800 322             182 757 243              168.55                               98.94
  CC12         203 133 950       183 665 658             183 629 660              164.16                               98.92
  CC13         195 342 238       176 816 668             176 779 527              163.11                               99.14
  CC14         215 392 940       192 504 740             192 468 467              176.64                               98.96
  CC15         186 503 740       168 736 670             168 699 555              150.49                               99.13
  CC16         188 775 628       173 447 948             173 418 659              160.24                               99.20
  CC17         189 597 468       174 502 714             174 458 692              157.42                               99.21
  CC18         179 218 892       164 454 320             164 426 639              153.55                               98.96
  CC20         179 435 082       165 011 368             164 988 404              155.39                               98.95
  CC21         195 883 102       179 886 726             179 858 958              168.34                               99.21
  CC24         173 198 708       159 597 160             159 569 988              153.26                               98.92
  Average      157 261 395       141 613 056             141 585 208              119.47                               98.78
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![Overview of our approach used to identify variants](CAM4-8-3738-g001){#cam42282-fig-0001}

3.2. CRC‐associated oncogene variants {#cam42282-sec-0008}
-------------------------------------

### 3.2.1. *RAS* mutations {#cam42282-sec-0009}

Overall, *RAS* mutations were present in 28.13% of our CRC patients (Figure [2](#cam42282-fig-0002){ref-type="fig"}). The most common *RAS* mutations were *KRAS* mutations in exon 2 (codons 12 and 13), including G12V (44.44%), G12C (11.11%), and G13D (11.11%). Beyond the well‐established point mutations in codons 12 and 13 of exon 2 of *KRAS*, we identified mutations in codon 117 of exon 4 (K117N, 11.11%) and codon 146 of exon 4 (A146T, 11.11%). One mutation (11.11%) in codon 68 (exon 3) of *NRAS* was also detected; this was a novel alteration (R68I). The non‐synonymous variant at locus 115256508 had a C‐to‐A change mapped in the small GTP‐binding protein domain, with an allele fraction of 21.19% (total reads 118, variant count 25) (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}A). Together, these non‐*KRAS* exon 2 mutations constituted 33.33% of all *RAS* mutations (Figure [3](#cam42282-fig-0003){ref-type="fig"}).

![Proportion of *RAS*, *RAF* mutations, and *RAS*/*RAF* wild‐type status identified by WES. WES, whole‐exome sequencing](CAM4-8-3738-g002){#cam42282-fig-0002}

![Proportion of *RAS* alterations identified by WES. WES, whole‐exome sequencing](CAM4-8-3738-g003){#cam42282-fig-0003}

### 3.2.2. *RAF* mutations {#cam42282-sec-0010}

Two *RAF* mutations were found in 9.38% of our patients (Figure [2](#cam42282-fig-0002){ref-type="fig"}). Two patients (6.25%) had *BRAF* V600E mutations. One patient (3.13%) had an *ARAF* T256fs mutation. None of the CRC patients with *RAS* mutations harbored a concomitant mutation in *RAF*. The remaining patients (62.5%) were *RAS*/*RAF* wild‐type (Figure [2](#cam42282-fig-0002){ref-type="fig"}).

### 3.2.3. *PIK3CA* mutations {#cam42282-sec-0011}

Three patients (9.38%) had *PIK3CA* mutation tumors. The mutation variants were R38S, G118D, and D350Y; D350Y was a novel mutation. The non‐synonymous variant at locus 178921566 had a G‐to‐T change mapped in the phosphatidylinositol 3‐kinase, C2 domain, with an allele fraction of 17.53% (total reads 97, variant count 17) (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}B).

### 3.2.4. *TCF7L2* mutations {#cam42282-sec-0012}

Two patients (6.25%) had *TCF7L2* mutation tumors. The identified variants were R471C, F357L, and G424E, and each patient had two of the three *TCF7L2* variants.

### 3.2.5. *SOX9* mutations {#cam42282-sec-0013}

Three patients (9.38%) had *SOX9* frameshift mutations. One patient had an S431fs mutation, another a G484fs mutation, and the third an S485fs mutation. The G484fs and S485fs mutations were novel variants (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}C).

3.3. CRC‐associated tumor suppressor gene variants {#cam42282-sec-0014}
--------------------------------------------------

### 3.3.1. *APC* mutations {#cam42282-sec-0015}

In total, we identified 19 patients (59.38%) with *APC* alterations. A total of 26 *APC* mutations were identified in the 19 samples, most of which were nonsense mutations that introduced a premature stop codon (R283\*, S320\*, Q541\*, R564\*, R876\*, R1114\*, Q1294\*, E1309\*, Q1367\*, Q1378\*, R1450\*, E1544\*, Q1916\*, and R2204\*). Six variants were frameshift deletions (L620fs, D1297fs, E1306fs, G1312fs, E1374fs, and E1397fs), 5 were frameshift insertions (L540fs, L852fs, T1292fs, L1302fs, and E1554fs,), and 1 was a missense mutation (S1400L). Among these mutations, 7 novel mutations were found (L540fs, T1292fs, D1297fs, L1302fs, E1306fs, E1374fs, and Q1916\*) (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}D).

### 3.3.2. *TP53* mutations {#cam42282-sec-0016}

Overall, *TP53* mutations were present in 50% of our CRC patients. Fifteen *TP53* mutations were identified in the 16 samples. All variants have been reported (L43fs, K132N, P151S, R175H, C176F, R196\*, L206\*, M237I, R245C, M246R, E258K, R273H, R273C, R282W, and R306\*).

### 3.3.3. *FBXW7* mutations {#cam42282-sec-0017}

Six of the 32 samples (18.75%) had a mutation in *FBXW7*. Four *FBXW7* variants were found in the 6 samples. All variants have been reported (G80W, W307C, R347H, and R387C).

### 3.3.4. *SMAD4* mutations {#cam42282-sec-0018}

Three patients (9.38%) had *SMAD4* mutations. Two variants have been reported previously (G419R and R496H), and the other was novel (Y260_H261delins\*). The frameshift variant at locus 48584605 had an A insertion with an allele fraction of 22.18% (total reads 284, variant count 63) (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}E).

3.4. Mismatch repair (MMR) gene variants {#cam42282-sec-0019}
----------------------------------------

### 3.4.1. *MLH1, MSH3, MSH4*, *PMS1*, and *PMS2* mutations {#cam42282-sec-0020}

Five patients (15.63%) had mismatch repair (MMR) gene mutations. Mutations in the MMR gene included *MLH1*, *MSH3, MSH4*, *PMS1*, and *PMS2*. The mutation variants were R385C and T117M in *MLH1*, A61delinsAAPA and E456K in *MSH3*, E583\* in *MSH4*, R265Q in *PMS1*, and L633I in *PMS2*. Among these, *MSH3* A61delinsAAPA and E456K, *MSH4* E583\*, *PMS1* R265Q, and *PMS2* L633I were novel mutations (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}F‐I). The numbers of variants discovered in the MMR wild‐type and mutation carriers are listed in Tables [S1](#cam42282-sup-0001){ref-type="supplementary-material"} and [S2](#cam42282-sup-0001){ref-type="supplementary-material"}.

3.5. Altered signaling pathways in CRC {#cam42282-sec-0021}
--------------------------------------

Based on our analytical approach, we identified multiple genes in the RTK‐RAS, PI3K, TGF‐β, WNT, and P53 pathways. The *APC* gene in the WNT pathway had relatively high levels of somatic mutations compared to genes in the RTK‐RAS, PI3K, TGF‐β, and P53 pathways. We found 10 different altered WNT pathway genes, including *LRP5*, *FZD10*, *APC*, *AXIN2*, *FAM123B*, *CTNNB1*, *TCF7L2*, *SOX9*, *FBXW7*, and *ARID1A*, confirming the importance of this pathway in CRC. We found that 78.13% of tumors had alterations in the WNT pathway. We also evaluated genetic alterations in the RTK‐RAS, PI3K, TGF‐β, and P53 pathways, with mutation rates of 40.63%, 15.63%, 18.75%, and 56.25%, respectively (Figure [4](#cam42282-fig-0004){ref-type="fig"}).

![Frequency of genetic changes leading to deregulation of signaling pathways in CRC. CRC, colorectal cancer](CAM4-8-3738-g004){#cam42282-fig-0004}

3.6. Pathway mutations and associations {#cam42282-sec-0022}
---------------------------------------

We compared the clinicopathological data of CRC patients with mutations in mutation‐related pathways. The RTK‐RAS pathway mutation rate was significantly higher in patients with a tumor size ≤4 cm compared to those with a tumor of \>4 cm (57.89% versus 15.38%, *P* = 0.028). No clinicopathological variables were significantly correlated with WNT, PI3K, TGF‐β, or P53 pathway mutations (Table [3](#cam42282-tbl-0003){ref-type="table"}).

###### 

Correlation between clinicopathological features and mutational status

                  Mutation of WNT pathway   Mutation of RTK‐RAS pathway   Mutation of PI3K pathway   Mutation of TGF‐β pathway   Mutation of P53 pathway                                                                                       
  --------------- ------------------------- ----------------------------- -------------------------- --------------------------- ------------------------- ---- ---- ---- ------- ---- ---- ---- ------- ---- ---- ---- ------- ---- ---- ---- -------
  Gender          F                         3                             9                          12                          1.000                     7    5    12   1.000   10   2    12   1.000   11   1    12   0.370   4    8    12   0.471
  M               4                         16                            20                                                     12                        8    20        17      3    20        15      5    20        10      10   20        
  Age             \<62                      3                             13                         16                          1.000                     10   6    16   1.000   15   1    16   0.333   13   3    16   1.000   5    11   16   0.285
  ≥62             4                         12                            16                                                     9                         7    16        12      4    16        13      3    16        9       7    16        
  Tumor Size      ≤4 cm                     3                             16                         19                          0.401                     8    11   19   0.028   17   2    19   0.375   15   4    19   1.000   10   9    19   0.289
  \>4 cm          4                         9                             13                                                     11                        2    13        10      3    13        11      2    13        4       9    13        
  Stage           I, II                     3                             16                         19                          0.384                     12   7    19   1.000   15   4    19   0.624   16   3    19   0.653   7    12   19   0.710
  III, IV         4                         8                             12                                                     7                         5    12        11      1    12        9       3    12        6       6    12        
  Site            Rectum                    3                             5                          8                           0.327                     5    3    8    1.000   6    2    8    0.578   8    0    8    0.296   4    4    8    0.704
  Colon           4                         20                            24                                                     14                        10   24        21      3    24        18      6    24        10      14   24        
  LN metastasis   −                         3                             16                         19                          0.401                     12   7    19   0.720   15   4    19   0.625   16   3    19   0.666   7    12   19   0.473
  \+              4                         9                             13                                                     7                         6    13        12      1    13        10      3    13        7       6    13        

*P*‐Value by Fisher\'s Exact Test.
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4. DISCUSSION {#cam42282-sec-0023}
=============

All of the mutated genes discussed in our study have been previously classified as driver genes that confer a selective growth advantage to tumor cells harboring the mutations. CRC is similar to other cancers with only one or multiple driver gene mutations. Tumors with only one driver mutation, always in an oncogene, and with multiple driver mutations contain a combination of oncogene and tumor suppressor gene mutations.[15](#cam42282-bib-0015){ref-type="ref"} In our study, of the 4 samples with a single mutation (Table [4](#cam42282-tbl-0004){ref-type="table"}), 1 (25%) harbored a mutation in an oncogene (*KRAS*), and of the 22 samples with 2 or more mutations (Tables [5](#cam42282-tbl-0005){ref-type="table"} and [6](#cam42282-tbl-0006){ref-type="table"}), 15 (68.18%) contained a combination of mutations in both oncogenes and tumor suppressor genes.

###### 

Single point mutations detected in 32 colorectal cancer samples

  Genes    Mutation          Sex   Age (years)   Differentiation   AJCC stage
  -------- ----------------- ----- ------------- ----------------- ------------
  *TP53*   p.K132N           F     57            Middle            IVB
  *APC*    p.Q1294\*         M     57            Middle            IIIB
  *MSH3*   p.A61delinsAAPA   M     61            Middle            IIA
  *KRAS*   p.G12C            F     69            Middle            IIA
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###### 

Double combination mutations detected in 32 colorectal cancer samples

  -----------------------------------------------------------------------------------------------
  Gene 1   Mutation 1   Gene 2    Mutation 2   Sex   Age (years)   Differentiation   AJCC stage
  -------- ------------ --------- ------------ ----- ------------- ----------------- ------------
  *ARAF*   p.T256fs     *FBXW7*   p.W307C      M     65            Middle to Low     NA

  *APC*    p.Q1916\*    *MLH1*    p.T117M      M     72            Middle            IIA

  *KRAS*   p.G12V       *TP53*    p.C176F      F     57            Middle            IIIB

  *APC*    p.Q1367\*    *TP53*    p.R282W      M     61            Middle            IIIB

  *SOX9*   p.G485fs     *APC*     p.R283\*     F     78            Middle            IIA

  *APC*    p.L540fs\    *TP53*    p.L43fs      M     35            Middle            IIA
           p.R1450\*                                                                 

  *KRAS*   p.G12V       *APC*     p.R564\*\    M     68            Middle            IIA
                                  p.L1302fs                                          

  *APC*    p.Q541\*     *TP53*    p.M246R      F     58            Middle            IIA

  *APC*    p.L620fs\    *TP53*    p.L206\*     F     47            Middle            I
           p.E1306fs                                                                 

  *APC*    p.S320\*\    *FBXW7*   p.R387C      F     42            Middle            IIIB
           p.E1544\*                                                                 
  -----------------------------------------------------------------------------------------------
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###### 

Three or more combination mutations detected in 32 colorectal cancer samples

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene 1     Mut. 1      Gene 2     Mut. 2       Gene 3     Mut. 3       Gene 4    Mut. 4                Gene 5   Mut.5      Gene 6   Mut. 6    Gene 7   Mut. 7    Sex   Age   Diff     AJCC stage
  ---------- ----------- ---------- ------------ ---------- ------------ --------- --------------------- -------- ---------- -------- --------- -------- --------- ----- ----- -------- ------------
  *BRAF*     p.V600E     *TP53*     p.E258K      *FBXW7*    p.G80W                                                                                                 M     55    Low      IVB

  *KRAS*     p.G12V      *APC*      p.E1554fs    *TP53*     p.R175H                                                                                                F     63    M        IIA

  *SOX9*     p.S431fs    *APC*      p.L852fs\    *TP53*     p.R196\*                                                                                               M     63    M         
                                    p.T1292fs                                                                                                                                           

  *KRAS*     p.G13D      *APC*      p.Q1378\*    *FBXW7*    p.R347H                                                                                                M     63    M        I

  *APC*      p.E1374fs   *TP53*     p.R273C      *SMAD4*    p.R496H                                                                                                M     68    M        IIA

  *KRAS*     p.A146T     *APC*      p.G1312fs    *TP53*     p.P151S      *MLH1*    p.R385C                                                                         F     45    M        IIA

  *NRAS*     p.R68I      *APC*      p.E1397fs    *TP53*     p.R245C\     *FBXW7*   p.R347H                                                                         M     48    M        I
                                                            p.R282W                                                                                                                     

  *PIK3CA*   P.G118D     *APC*      p.D1297fs    *FBXW7*    p.R387C      *TP53*    p.R273H                                                                         F     67    M        IIA

  *KRAS*     p.G12V      *TP53*     p.R273C      *SMAD4*    p.G419R      SOX9      p.S484fs                                                                        F     64    L        IIA

  *BRAF*     p.V600E     *APC*      p.Q1294\*\   *TP53*     p.M237I      *SMAD4*   p.Y260_H261delins\*                                                             M     44    M        IVB
                                    p.E1554fs                                                                                                                                           

  *KRAS*     p.K117N     *PIK3CA*   p.R38S       *TCF7L2*   p.R471C\     *APC*     p.R876\*\             *MSH4*   p.E583\*                                         M     71    M to L   IIIC
                                                            p.G424E                p.E1309\*\                                                                                           
                                                                                   p.R2204\*                                                                                            

  *PIK3CA*   p.D350Y     *TCF7L2*   p.F357L\     *APC*      p.R1114\*\   *TP53*    p.R306\*              *MSH3*   p.E456K    *PMS1*   p.R265Q   *PMS2*   p.L633I   M     50    M        IIA
                                    p.R471C                 p.Q1378\*\                                                                                                                  
                                                            p.S1400L                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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The integrative analysis of WES data provides insights into pathways that are dysregulated in CRC. The WNT signaling pathway was dysregulated in 78.13% of cases. WNT pathway mutations have been reported in 84.5%% of CRC cases, which is higher than the mutation rate detected in our study.[16](#cam42282-bib-0016){ref-type="ref"} In 2012, the TCGA consortium reported that up to 93% of CRC cases involved at least 1 alteration in a known WNT regulator.[6](#cam42282-bib-0006){ref-type="ref"} Hyperactivation of the WNT pathway initiates the development of CRC, which predominantly occurs through inactivation of the *APC* gene.[17](#cam42282-bib-0017){ref-type="ref"} Several agents have been investigated to target this pathway, including WNT inhibitors (eg, Rofecoxib, PRI‐724, CWP232291) and a monoclonal antibody against frizzled receptors (e.g., vanituctumab).[18](#cam42282-bib-0018){ref-type="ref"} In addition to *APC* and *SOX9*, we also identified a novel mutation in *AXIN2* (p.R459L) (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}J). The *AXIN2* mutation identified in the current study, R459, is located in the region that interacts with β‐catenin.

The frequency of alterations in the RTK‐RAS and PI3K pathways was 40.63% and 15.63%, respectively. RTK‐RAS and PI3K pathway mutations have been found in 60.7% and 30% of CRCs, respectively.[16](#cam42282-bib-0016){ref-type="ref"} In a normal cell, RTK‐RAS and PI3K pathways control cell proliferation, differentiation, and survival.[19](#cam42282-bib-0019){ref-type="ref"}, [20](#cam42282-bib-0020){ref-type="ref"} In a malignant cell, constitutive and aberrant activation of components of these pathways lead to increased cell growth, survival, and metastasis. Small molecule inhibitors, such as Sorafenib and PLX4720, which are currently being used to target BRAF p.V600E, have been developed to target the RTK‐RAS and PI3K pathways. NVP‐BEZ235 and BGT226 are being used to target the PI3K pathway in various cancers.[21](#cam42282-bib-0021){ref-type="ref"} In addition to *NRAS* and *PIK3CA*, we identified two novel mutations in *ERBB2* (p.W9fs) and *PIK3R1* (p.S147\* and p.L161\*) (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}K,L). The *PIK3R1* p.S147\* and p.L161\* mutations were mapped to the Rho GTPase‐activating protein domain.

In our study population, the mutation rate of the TGF‐β and P53 pathways was 18.75% and 56.25%, respectively. TGF‐β and P53 pathway mutations have been described in 28.9% and 69% of CRCs, respectively.[16](#cam42282-bib-0016){ref-type="ref"} The TGF‐β signaling pathway has pleiotropic functions, including the regulation of cell growth, apoptosis, cell motility, and invasion. TGF‐β signaling plays a key role in tumor initiation, development, and metastasis. Many TGF‐β pathway inhibitors, such as antisense oligonucleotides, neutralizing antibodies, and receptor kinase inhibitors, have been used in preclinical trials. For example, galunisertib is a TGFβR1 inhibitor that prevents signal transduction.[22](#cam42282-bib-0022){ref-type="ref"} Under cellular stress, such as DNA damage, oncogenes, oxidative free radicals, and UV irradiation, the P53 protein is activated. Activation of P53 can induce cell cycle arrest, senescence, and apoptosis. Small molecular inhibitors, such as MIs, nutlins, and RITA, have been tested as therapeutic agents in CRC by activating this pathway.[23](#cam42282-bib-0023){ref-type="ref"} In addition to *SMAD4*, we identified a novel mutation in *TGFBR2* (p.D549A) and *ATM* (p.E650\*) (Figure [S1](#cam42282-sup-0001){ref-type="supplementary-material"}M,N). Our relatively low rate of mutations in these 5 critical pathways may reflect our small sample size.

Most CRC samples can be grouped by WNT‐, RTK‐RAS‐, P53‐, TGF‐β‐, and PI3K‐dysregulated pathways. In our study population, 3 samples (3/32, 9.38%) had no mutation in any of these pathways. However, in these 3 samples, 2 had alterations in the Notch signaling pathway (*CTBP2*, *CREBBP*, *KAT2B*, *DVL2*, and *PSEN2*). Deregulation of Notch signaling in CRC has been reported.[24](#cam42282-bib-0024){ref-type="ref"} The third sample exhibited alterations in cell adhesion molecules (*CNTN2*, *HLA‐DRB1*, *HLA‐DRB5*, and *NRXN3*). This indicates that it may be necessary to identify other dysregulated pathways to achieve therapeutic benefits.

We also compared the clinicopathological data of CRC patients with the mutational status of important signaling pathways in cancerous tissues. RTK‐RAS pathway mutations were correlated with tumor size (*P* = 0.028). These results suggest that tumor progression is not linked to increased genetic instability, although this may be due to our small sample size and fact that most cases were stage II (48.39% cases); we need to collect more samples to confirm our results.

In conclusion, we identified recurrent mutations in genes such as *APC*, *TP53*, *KRAS*, and *FBXW7*, as well as unreported mutations in *NRAS*, *PIK3CA*, *SOX9*, *APC*, *SMAD4*, *MSH3*, *MSH4*, *PMS1 PMS2*, *AXIN2*, *ERBB2*, *PIK3R1*, *TGFBR2*, and *ATM* in a group of Taiwanese CRC patients. The data presented herein provide more comprehensive characteristics of the top deadly disease and identify a possibility for treating it in a targeted way.
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